• CervoMed to Participate in the Emerging Growth Conference

    Источник: Nasdaq GlobeNewswire / 17 июл 2024 07:00:00   America/Chicago

    BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will present virtually at the Emerging Growth Conference.

    Presentation Details
    Format: Corporate presentation
    Date: Thursday, July 18, 2024
    Time: 1:10 PM ET
    Webcast Link: click here

    The webcast of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

    About CervoMed
    CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

    Investor Contact:
    PJ Kelleher
    LifeSci Advisors
    Investors@cervomed.com
    617-430-7579


    Primary Logo

Опубликовать